Business
Coverage Initiated for Endonovo Therapeutics via NetworkNewsWire
Coverage Initiated for Endonovo Therapeutics via NetworkNewsWire.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\nNEW YORK, May 29, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company developing a bioelectronic approach to regenerative medicine, today announces it has selected the corporate communications expertise of NetworkNewsWire (\"NNW\").\n Endonovo’s non-invasive medical devices are designed to deliver its proprietary Electroceutical™ Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. Endonovo's Electroceutical™ therapeutic device, SofPulse® is FDA-cleared for the promotion of the palliative treatment of post-surgical pain and edema (swelling) and CE Marked for the promotion of wound healing and the palliative treatment of post-surgical pain and edema, and has received CMS National Coverage for the treatment of chronic wounds. The Company's current pipeline of clinical-stage Electroceutical™ Therapies targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis. NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility. As part of the Client-Partner relationship with Endonovo, NNW will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the company. “While Endonovo focuses on the advancement of its products to improve the patient’s post-operative experience, we will execute a corporate communications campaign that places its strategy and accomplishments in front of the investment community,” states Sherri Franklin, Director of Client Solutions for NNW. About Endonovo Therapeutics Endonovo Therapeutics Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses ...